215 related articles for article (PubMed ID: 37062069)
1. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract][Full Text] [Related]
2. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
3. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
4. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
5. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
6. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
7. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
8. Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function.
Lucio-Eterovic AK; Singh MM; Gardner JE; Veerappan CS; Rice JC; Carpenter PB
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16952-7. PubMed ID: 20837538
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
10. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
11. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
Rathert P
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
[TBL] [Abstract][Full Text] [Related]
12. High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.
Shen Y; Morishita M; di Luccio E
Protein Expr Purif; 2020 Feb; 166():105506. PubMed ID: 31563542
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
14. Computational analyses on genetic alterations in the NSD genes family and the implications for colorectal cancer development.
D'Afonseca V; Gónzalez G; Salazar M; Arencibia AD
Ecancermedicalscience; 2020; 14():1001. PubMed ID: 32153656
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.
Sun Y; Xie J; Cai S; Wang Q; Feng Z; Li Y; Lu JJ; Chen W; Ye Z
Cell Death Dis; 2021 Oct; 12(10):913. PubMed ID: 34615858
[TBL] [Abstract][Full Text] [Related]
16. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
Allali-Hassani A; Kuznetsova E; Hajian T; Wu H; Dombrovski L; Li Y; Gräslund S; Arrowsmith CH; Schapira M; Vedadi M
J Biomol Screen; 2014 Jul; 19(6):928-35. PubMed ID: 24595546
[TBL] [Abstract][Full Text] [Related]
17. Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.
Shipman GA; Padilla R; Horth C; Hu B; Bareke E; Vitorino FN; Gongora JM; Garcia BA; Lu C; Majewski J
bioRxiv; 2023 Oct; ():. PubMed ID: 37905045
[TBL] [Abstract][Full Text] [Related]
18. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
Wang GG; Cai L; Pasillas MP; Kamps MP
Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
[TBL] [Abstract][Full Text] [Related]
19. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.
Angrand PO; Apiou F; Stewart AF; Dutrillaux B; Losson R; Chambon P
Genomics; 2001 May; 74(1):79-88. PubMed ID: 11374904
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.
Kim S; Hwang I; Kim SH; Chung HW; Ji MJ; Moon S; Park HM; Kong G; Hur W
Chem Biol Drug Des; 2023 Sep; 102(3):500-513. PubMed ID: 37072259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
